Navigation Links
Abbott's XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial
Date:9/23/2009

SAN FRANCISCO, Sept. 23 /PRNewswire-FirstCall/ -- Late-breaking data presented today from the COMPARE trial demonstrated that Abbott's (NYSE: ABT) market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System demonstrated significantly better outcomes in key safety and efficacy measures compared to the TAXUS(R) Liberte Paclitaxel-Eluting Coronary Stent System (TAXUS). At one year, XIENCE V demonstrated a significantly lower incidence of major adverse cardiac events (MACE) compared to TAXUS (6.2% XIENCE V vs. 9.1% TAXUS, p-value= 0.023) in the trial's primary endpoint, which is a composite of all death, non-fatal heart attack (myocardial infarction) and target vessel revascularization (TVR). Additionally, XIENCE V demonstrated a significantly lower rate of stent thrombosis compared to TAXUS (0.7% XIENCE V vs. 2.6% TAXUS, p-value=0.002), a significantly lower rate of TVR (2.4% XIENCE V vs. 6.0% TAXUS, p-value=0.0001), and a significantly lower rate of TLR (1.7% XIENCE V vs. 4.8% TAXUS, p-value=0.0002).

The results from the COMPARE trial were presented by Peter Smits, M.D., of Maasstad Ziekenhuis, Rotterdam, the Netherlands, during the 2009 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.

"The COMPARE trial, which studied a real-world, complex patient population, reaffirms what we saw in SPIRIT IV earlier today and what we've seen throughout our SPIRIT family of trials - with XIENCE V showing consistent, outstanding performance compared to TAXUS, whether it's TAXUS Express in SPIRIT IV or now TAXUS Liberte in the investigator-initiated study COMPARE," said John Capek, Ph.D., executive vice president, Medical Devices, Abbott.

About XIENCE V

XIENCE V is used to treat coronary artery disease by propping open a narrowed or blocked artery and releasing the drug, everolimus, in a controlled manner to prevent the artery from becoming blocked again following a stent procedure. XIENCE V is built upon Abbott's market-leading bare metal stent, the MULTI-LINK VISION(R) Coronary Stent System. The VISION platform is designed to facilitate ease of delivery, making it easier for physicians to maneuver the stent and treat the diseased portion of the artery.

The XIENCE V stent is available on both over-the-wire (OTW) and rapid exchange (RX) delivery systems. Rapid exchange is the most widely used type of delivery system because it provides physicians additional flexibility to work as single operators during stent procedures.

Abbott's market-leading XIENCE V drug eluting stent is commercially available in the United States, Europe and other international markets. XIENCE V is an investigational device in Japan and is currently under review by Japan's Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency.

Abbott also supplies a private-label version of XIENCE V to Boston Scientific called the PROMUS(R) Everolimus-Eluting Coronary Stent System. PROMUS is designed and manufactured by Abbott and supplied to Boston Scientific as part of a distribution agreement between the two companies.

Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its anti-proliferative properties.

XIENCE V is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (lesions less than or equal to 28 mm) with reference vessel diameters of 2.5 mm to 4.25 mm. Additional information about XIENCE V, including important safety information, is available online at www.xiencev.com or www.abbottvascular.com/en_US/content/document/eIFU_XienceV.pdf.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbotts XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
2. Abbotts XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
3. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
4. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
5. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
6. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
7. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
8. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
9. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
10. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
11. MoxDuo(TM) IR Demonstrates Fewer Side Effects Than Percocet(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... VAE, January 20, 2017 ... Bedarf an Nothilfe   Die internationale humanitäre Stadt ... Hilfsgüter zu schaffen   Seine Hoheit ... der VAE sowie Herrscher von Dubai ... Stadt der Hilfe (International Humanitarian City IHC) zu verdreifachen, ...
(Date:1/19/2017)... 2017 The Global Therapy Partnering Terms and ... partnering deals and agreements entered into by the world,s ... - Top deals by value - Deals listed by ... The report provides understanding and access to the ... leading healthcare companies. The report provides an analysis ...
(Date:1/19/2017)... CITY, N.J. , Jan. 19, 2017 ... over $100 for their medication when a pharmacy just ... same exact prescription.  To alleviate this problem Medicationdiscountcard.com ... and patients to see exactly how much their medication ... Comparison Shopping Made Easy ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... 20, 2017 , ... “Knowledge is God’s Lighthouse”: a moving and colorful ... Lighthouse” is the creation of published author, Gene Gaapf, a retired truck driver, and ... “I have been writing since high school and have many different titles,” Gaapf mentions ...
(Date:1/19/2017)... ... ... Today, the Centers for Medicare & Medicaid Services (CMS) announced over 359,000 clinicians ... 2017. Clinicians who participate in APMs are paid for the quality of care they ... to build a system that delivers better care and one in which clinicians work ...
(Date:1/19/2017)... ... January 19, 2017 , ... Wells Pharmacy ... enhancement of their 503A compounding pharmacy located in Ocala, Florida. , Meeting ... and patients throughout the United States for high-quality human anti-aging and wellness ...
(Date:1/19/2017)... Linda, Ca (PRWEB) , ... January 19, 2017 ... ... virtual events for tech innovators, engineers, and scientists from around the world, announces ... site offers users a quick and easy portal to research breakthroughs and trending ...
(Date:1/19/2017)... ... January 19, 2017 , ... Cosmetic Town, an online plastic surgery ... order to make it easier for their readers to get the information they desire. ... as well as the techniques used on those particular areas. , “We are excited ...
Breaking Medicine News(10 mins):